Efficacy and tolerability of prostaglandin–timolol fixed combinations: an updated systematic review and meta-analysis

Lou, Heng; Wang, Hao; Zong, Ying; Cheng, Jin-Wei; Wei, Rui-Li

doi:10.1185/03007995.2015.1039504

Cited by 16 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This systematic review included studies with normal-tension glaucoma or pseudoexfoliative glaucoma patients, but we excluded these studies. Another meta-analysis involving four clinical trials found that LTFC was significantly worse than BiTFC in reducing the diurnal mean IOP (MD = 0.88 mmHg) [8]. We note that there was significant heterogeneity in this analysis (I 2 = 66%, P = 0.03), and sensitivity analysis showed that the study center (single or multiple) may have been the main contributor to this heterogeneity.…”

Section: Discussionmentioning

confidence: 70%

See 1 more Smart Citation

The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background Fixed-combination (FC) therapy is used in primary open-angle glaucoma (POAG) and ocular hypertension (OHT) patients who require more than one medication to reach their target intraocular pressure (IOP). Currently, there are several FC therapies available for the treatment of glaucoma. The FC of latanoprost/timolol (LTFC) is a commonly used FC. Here, we conducted systematic review to compare the IOP-lowering effects of LTFC with other FCs for patients with POAG and OHT. Materials and methods We searched PubMed, EMBASE, the Cochrane Library, and Web of Science for randomized-controlled clinical trials and cross-over studies. The outcomes were mean IOP and IOP fluctuation after one month of treatment. Meta-analysis was carried out using RevMan (version 5.1) software. After conducting meta-analyses, we rated the quality of each meta-analysis as high, moderate, low, or very low using the "GRADE" system. Results We included 16 trials in this meta-analysis. Moderate-quality meta-analysis showed that LTFC had a comparable mean IOP to that of a fixed combination of travoprost and timolol (TTFC) [mean difference (MD): 0.07 mmHg] and a fixed combination of dorzolamide and timolol (DTFC) [MD: −0.31 mmHg], and it also had a comparable IOP-fluctuation effect compared to that of TTFC [MD: 0.13 mm Hg] and DTFC [MD: 0.25 mmHg]. Compared to the fixed combination of bimatoprost and timolol (BiTFC), moderate-quality evidence showed a higher mean IOP in the LTFC group [MD 0.76 mmHg], whereas low-quality meta-analysis showed higher IOP fluctuation [MD 1.09 mmHg] in the LTFC group.

show abstract

Section: Discussionmentioning

confidence: 70%

“…There are some meta-analyses [5,6,7,8] that have studied the comparative effectiveness of fixed combinations from different aspects. For example, some meta-analyses [5,6] studied the relative IOP reduction with indirect comparisons.…”

Section: Discussionmentioning

confidence: 99%

The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“… 10 , 38 , 39 As a recent systematic review concludes, bimatoprost/timolol FC in particular seems to achieve better reduction of IOP compared to other prostaglandin-timolol combinations containing latanoprost or travoprost. 40 A clinical trial comparing all FCs to each other in terms of IOP reduction rate is therefore required to establish a reliable foundation.…”

Section: Discussionmentioning

confidence: 99%

Selective Laser Trabeculoplasty vs. Fixed Combinations with Timolol in Practice: A Replacement Study in Primary Open Angle Glaucoma

Tufan¹,

Onur²,

Yigit³

et al. 2017

tjo

View full text Add to dashboard Cite

Objectives:To evaluate the potential of selective laser trabeculoplasty (SLT) in two arms (360˚ vs. 180˚) as a replacement for fixed combinations (FCs) with timolol in primary open angle glaucoma over 6 months.Materials and Methods:Of 40 patients in a prospective, comparative, interventional case series, 18 eyes and 22 eyes were randomized to SLT 180º and SLT 360º groups, respectively, along with 40 fellow-control eyes. FC with timolol was discontinued on the day of treatment for the eye to be operated on, while ongoing therapy was not interrupted for the contralateral eye. Eyes were examined for intraocular pressure (IOP) elevation 1 hour and 1 day after SLT. The follow-up visits were then scheduled for 1 week, 1 month, 3 months, and 6 months after, during the which the IOP of both eyes and any possible complications were evaluated.Results:There were no statistically significant differences in mean IOPs through 6 months among the groups with exception of postlaser 1 hour and postlaser 1 day (p<0.001 and p=0.010, respectively). Multiple comparison analysis showed significantly higher IOP in both SLT 180º and SLT 360º subgroups compared to their controls at postlaser 1 hour (p=0.007, p<0.001) but significantly lower IOP only in SLT 360º subgroup compared to the controls at postlaser day 1 (p=0.013).Conclusion:SLT offers promising potential as a substitute equivalent to efficacy of FCs with timolol. However, SLT 360˚ may not achieve additional IOP reduction.

show abstract

“…There is meta-analysis evidence to indicate that the bimatoprost-timolol combination has the most powerful IOP-lowering effect of the PGA-timolol combinations. 85 Pilocarpine tends not to be added to a patient already receiving four different drugs classes, but it is plausible. In addition, oral acetazolamide could also be added, and in some cases, the clinician may decide that a 'belts and braces' approach is prudent.…”

Section: Maximal Tolerated Medical Therapymentioning

confidence: 99%

Medical therapy for glaucoma: A review

Casson

2022

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

A number of pharmacological targets are exploited to modify the parameters in the Goldmann equation and reduce the intraocular pressure (IOP). This strategy constitutes the foundation for the medical management of glaucoma, the evolution of which, until only recently, has been in relative stagnation. A burst of innovation has produced new ocular hypotensive drugs and longacting delivery methods, including intracameral delivery, which are expanding the clinician's medical armamentarium. A number of IOP-independent neuroprotection strategies have shown strong potential in animal models of glaucoma, but translational attempts have been surprisingly limited. However, while pharmacological options are expanding, the traditional role of topical medical therapy is being challenged by selective laser trabeculoplasty, microinvasive glaucoma surgery, and sustained delivery methods. A scientifically rigorous assessment of new treatments will be critical to empower clinicians with evidence-based information to optimise vision preservation and quality of life outcomes for their patients.

show abstract

Efficacy and tolerability of prostaglandin–timolol fixed combinations: an updated systematic review and meta-analysis

Cited by 16 publications

References 21 publications

The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis

The efficacy of the fixed combination of latanoprost and timolol versus other fixed combinations for primary open-angle glaucoma and ocular hypertension: A systematic review and meta-analysis

Selective Laser Trabeculoplasty vs. Fixed Combinations with Timolol in Practice: A Replacement Study in Primary Open Angle Glaucoma

Medical therapy for glaucoma: A review

Contact Info

Product

Resources

About